Dr. Jin-San Yoo is CEO, President and Founder of PharmAbcine, leading clinical stage biotech company in Korea. He successfully closed his series A in the middle of global economy crises from Novartis Venture Fund and OrbiMed. Prior to founding PharmAbcine, Dr. Yoo was head of "The Therapeutic Antibody Center" (TTAC) at Korea Research Institute of Biotechnology and Biosciences (KRIBB) for 3 years, Dr. Yoo spent more than 5 years at LG Life Sciences, Ltd. as director of "Therapeutic Antibody Division (TAD)" to establish infrastructure and pipelines for antibody therapeutic business. Prior to LG Life Sciences, he worked for 3 years as TSRI Senior Associate at The Scripps Research Institute, CA, USA. Before Scripps, he was HHMI Associate at Howard Hughes Medical Institute (HHMI) at Stanford University School of Medicine, CA, USA for 3 years. He was trained as Intern, MS, PhD and MPI Fellow in the field of molecular cell biology at Max-Planck-Institute for BioPhysical Chemistry, Göttingen, Germany. Dr. Yoo studied microbiology and organic chemistry as undergraduate at the Georg-August-University Göttingen, Germany. He has authored numerous papers in peer reviewed journals, book chapters and he is also an inventor of several patents and patent applications.